- ongoing, recruitingTherapeutic exploratory (Phase II)
A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT)
This study looks at a new cell treatment for severe GvHD in adults after a stem cell transplant. It compares the new treatment with standard care to see if it's safe and helps improve patient conditions and how long that improvement lasts.
Sweden · Norway · Denmark - ongoing, recruitingTherapeutic confirmatory (Phase III)
Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG
This study compares two ways to prevent a serious complication called graft-versus-host disease (GvHD) after a certain type of blood stem cell transplant. It aims to find out which method helps people live longer and stay healthier after their transplant.
Germany - active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
United States · Australia · Canada - recruitingNA
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
This study looks into how a treatment called extracorporeal photochemotherapy (ECP) works at a cellular level. ECP helps people with certain blood cancers, transplant rejection, and graft-versus-host disease by understanding how it affects cells.
France